专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR1020020030497A 오스테놀 유도체 및 이를 포함하는 전립선질환 예방 또는 치료용 조성물 有权
标题翻译： OSTENOL衍生物和5种ALPHA还原型II型抑制组合物
公开(公告)号：KR1020020030497A
公开(公告)日：2002-04-25
申请号：KR1020000061331
申请日：2000-10-18
申请人： 주식회사 바이오젠텍
发明人： 김경호 , 마응천 , 조명행 , 김상희
IPC分类号： C07D311/10
摘要： PURPOSE: An ostenol derivative and a 5 alpha-reductase type II inhibiting composition containing it are provided, thereby effectively inhibiting the activity of 5 alpha-reductase type II and consequently treating the prostate disease. CONSTITUTION: The ostenol derivative inhibiting the activity of 5 alpha-reductase type 2 is represented by formula(1), in which R1 is hydrogen, unsubstituted or mono or multi substituted C1 to C5 alkyl, C2 to C6 alkenyl or C2 to C6 alkynyl; C1 to C7 alkylcarbonyl; benzyl; or C3 to C7 allylcarbonyl or C3 to C7 allylcarbamyl; R2 is hydrogen; or unsubstituted or hydroxy or C1 to C5 alkyl-OCO substituted C2 to C5 alkyl or C2 to C6 alkenyl; or OR1 and R2 are together unsubstituted or substituted oxygen containing 5 or 6 member hetero ring, provided that R1 and R2 are not hydrogen at the same time.
摘要翻译：目的：提供含有它的奥斯坦醇衍生物和5α-还原酶II型抑制组合物，从而有效地抑制5型α-还原酶II的活性，从而治疗前列腺疾病。构成：抑制5型5α-还原酶2活性的奥雌醇衍生物由式（1）表示，其中R 1是氢，未取代或单取代或多取代的C 1 -C 5烷基，C 2至C 6烯基或C 2至C 6炔基; C1至C7烷基羰基; 苄基; 或C 3至C 7烯丙基羰基或C 3至C 7烯丙基氨基甲酰基; R2是氢; 或未取代的或羟基或C 1至C 5烷基-OCO取代的C 2至C 5烷基或C 2至C 6烯基; 或OR 1和R 2一起是未取代或取代的含5或6元杂环的氧，条件是R1和R2不同时为氢。

2. 发明授权

KR100386318B1 오스테놀 유도체를 포함하는 암 예방 및 치료용 조성물 失效
标题翻译： 오스테놀유도체를포함하는암예방및치료용조성물
公开(公告)号：KR100386318B1
公开(公告)日：2003-06-18
申请号：KR1020000069226
申请日：2000-11-21
申请人： 주식회사 바이오젠텍
发明人： 김경호 , 마응천 , 조명행 , 김상희
IPC分类号： C07D311/16
摘要： PURPOSE: Provided is a composition which contains osthenol derivative, its pharmaceutically acceptable salt and carrier and inhibits xanthine oxidase, inducible nitric oxide synthase or induces quinone reductase for the prevention and treatment of cancer associated with these enzymes. CONSTITUTION: The pharmaceutical composition contains osthenol derivative of the formula(1), and its pharmaceutically acceptable salt and carrier. In the formula(1), R1 is hydrogen; substituted or unsubstituted C1-C5 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; C1-C7 alkylcarbonyl; benzyl; or C-C7 allylcarbonyl or C3-C7 allylcarbamoyl; R2 is hydrogen; unsubstituted, or hydroxy or C1-C6 alkyl-OCO- substituted C2-C5 alkyl or C2-C6 alkenyl; or OR1 and R2 are substituted or unsubstituted together to form 5 or 6 membered hetero ring containing oxygen atom, provided that R1 and R2 are not hydrogen atoms simultaneously.
摘要翻译：目的：提供一种组合物，其含有苯菌酚衍生物，其药学上可接受的盐和载体并抑制黄嘌呤氧化酶，诱导型一氧化氮合酶或诱导醌还原酶用于预防和治疗与这些酶相关的癌症。组成：药物组合物含有式（1）的osthenol衍生物及其药学上可接受的盐和载体。在式（1）中，R 1是氢; 取代或未取代的C 1 -C 5烷基，C 2 -C 6烯基或C 2 -C 6炔基; C1-C7烷基羰基; 苄基; 或C 1 -C 7烯丙基羰基或C 3 -C 7烯丙基氨基甲酰基; R2是氢; 未取代的或羟基或C 1 -C 6烷基-OCO-取代的C 2 -C 5烷基或C 2 -C 6烯基; 或者OR 1和R 2一起被取代或未被取代以形成含有氧原子的5或6元杂环，条件是R 1和R 2不同时为氢原子。

3. 发明授权

KR100430141B1 오스테놀 유도체 및 이를 포함하는 전립선질환 예방 또는 치료용 조성물 有权
标题翻译： 오스테놀유도체및이를포함하는전립선질환예방또는치료용조성물
公开(公告)号：KR100430141B1
公开(公告)日：2004-05-03
申请号：KR1020000061331
申请日：2000-10-18
申请人： 주식회사 바이오젠텍
发明人： 김경호 , 마응천 , 조명행 , 김상희
IPC分类号： C07D311/10
摘要： PURPOSE: An ostenol derivative and a 5 alpha-reductase type II inhibiting composition containing it are provided, thereby effectively inhibiting the activity of 5 alpha-reductase type II and consequently treating the prostate disease. CONSTITUTION: The ostenol derivative inhibiting the activity of 5 alpha-reductase type 2 is represented by formula(1), in which R1 is hydrogen, unsubstituted or mono or multi substituted C1 to C5 alkyl, C2 to C6 alkenyl or C2 to C6 alkynyl; C1 to C7 alkylcarbonyl; benzyl; or C3 to C7 allylcarbonyl or C3 to C7 allylcarbamyl; R2 is hydrogen; or unsubstituted or hydroxy or C1 to C5 alkyl-OCO substituted C2 to C5 alkyl or C2 to C6 alkenyl; or OR1 and R2 are together unsubstituted or substituted oxygen containing 5 or 6 member hetero ring, provided that R1 and R2 are not hydrogen at the same time.
摘要翻译：目的：提供一种奥斯替诺衍生物和含有它的5α-还原酶II型抑制组合物，由此有效地抑制5α-还原酶II型的活性并因此治疗前列腺疾病。构成：抑制5α-还原酶2型活性的奥斯尼醇衍生物由式（1）表示，其中R1为氢，未取代的或单取代或多取代的C1-C5烷基，C2-C6链烯基或C2-C6炔基; C1至C7烷基羰基; 苄基; 或C 3至C 7烯丙基羰基或C 3至C 7烯丙基氨基甲酰基; R2是氢; 或未取代或羟基或C 1至C 5烷基-OCO取代的C 2至C 5烷基或C 2至C 6烯基; 或OR 1和R 2一起为未取代的或取代的含有5或6元杂环的氧，条件是R 1和R 2不同时为氢。

4. 发明公开

KR1020020039422A 오스테놀 유도체를 포함하는 암 예방 및 치료용 조성물 失效
标题翻译：用于预防和治疗含有OSTHENOL衍生物的癌症的组合物
公开(公告)号：KR1020020039422A
公开(公告)日：2002-05-27
申请号：KR1020000069226
申请日：2000-11-21
申请人： 주식회사 바이오젠텍
发明人： 김경호 , 마응천 , 조명행 , 김상희
IPC分类号： C07D311/16
摘要： PURPOSE: Provided is a composition which contains osthenol derivative, its pharmaceutically acceptable salt and carrier and inhibits xanthine oxidase, inducible nitric oxide synthase or induces quinone reductase for the prevention and treatment of cancer associated with these enzymes. CONSTITUTION: The pharmaceutical composition contains osthenol derivative of the formula(1), and its pharmaceutically acceptable salt and carrier. In the formula(1), R1 is hydrogen; substituted or unsubstituted C1-C5 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; C1-C7 alkylcarbonyl; benzyl; or C-C7 allylcarbonyl or C3-C7 allylcarbamoyl; R2 is hydrogen; unsubstituted, or hydroxy or C1-C6 alkyl-OCO- substituted C2-C5 alkyl or C2-C6 alkenyl; or OR1 and R2 are substituted or unsubstituted together to form 5 or 6 membered hetero ring containing oxygen atom, provided that R1 and R2 are not hydrogen atoms simultaneously.
摘要翻译：目的：提供含有苯酚衍生物，其药学上可接受的盐和载体并且抑制黄嘌呤氧化酶，诱导型一氧化氮合酶或诱导醌还原酶用于预防和治疗与这些酶相关的癌症的组合物。构成：药物组合物含有式（1）的苯酚衍生物及其药学上可接受的盐和载体。在式（1）中，R 1是氢; 取代或未取代的C 1 -C 5烷基，C 2 -C 6烯基或C 2 -C 6炔基; C 1 -C 7烷基羰基; 苄基; 或C-C7烯丙基羰基或C3-C7烯丙基氨基甲酰基; R2是氢; 未取代的或羟基或C 1 -C 6烷基-OCO-取代的C 2 -C 5烷基或C 2 -C 6烯基; 或OR 1和R 2一起被取代或未取代，形成含有氧原子的5或6元杂环，条件是R1和R2不同时为氢原子。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式